A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

Black people with multiple sclerosis (MS) may face higher mortality rates and more severe symptoms than white people, yet 98% of participants in recent MS drug trials were white. This lack of ...

An experimental MS therapy given as a nasal spray has started dosing its final participant in a Phase 2a trial of people with ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Dr. Alberto Ascherio (left) ...

NASHVILLE, Tennessee — For the first time, the majority of patients with multiple sclerosis (MS) in the United States are, or soon will be, over age 55, a phenomenon that's driving a shift in ...

Multiple sclerosis research focuses on the early years of life by Friederike Fellenberg, NAKO e.V. / NAKO Gesundheitsstudie edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

The National Multiple Sclerosis Society (NMSS) announced a number of new funding opportunities aimed to bolster MS research and training. Support originates both from the Society and outside entities.

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are not ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...